| SHAREHOLDERS’ EQUITY |
| NOTE
10: - |
SHAREHOLDERS’ EQUITY
|
| |
a. |
Composition of share capital:
|
| |
|
December
31, |
|
| |
|
2025
|
|
|
2024
|
|
| |
|
Authorized
|
|
|
Issued
and outstanding |
|
|
Authorized
|
|
|
Issued
and outstanding |
|
| |
|
Number
of Shares |
|
|
Number
of Shares |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary
shares of no-par value (1) |
|
|
500,000,000
|
|
|
|
214,090,980
|
|
|
|
500,000,000
|
|
|
|
169,397,030
|
|
| |
|
|
| |
(1) |
Ordinary shares confer upon the holders the right
to vote in annual and special meetings of the Company, and to participate in the distribution of the surplus assets of the Company
upon liquidation of the Company. |
| |
b. |
On August 14, 2023 and on September 12, 2023,
the Company issued a total of 26,352,878
ordinary shares of no-par value, at a public offering price of $2.5
per share, for a total consideration of $61,400,
net of underwriting discount and other issuance costs of $4,482.
|
| |
c. |
On February 12, 2025, the Company issued a total
of 28,776,978
ordinary shares of no-par value and 23,021,582
warrants to purchase one ordinary share, at an offering price of $1.39 per
unit (each unit consisting of one ordinary share and eight tenths of a warrant), for a total consideration of $37,289,
net of placement agent fees and other issuance costs of $2,711.
The warrants are immediately exercisable at $1.69 per
share and will expire five
years from the date of issuance. The warrants were classified as equity in the Company’s consolidated financial
statements. |
| |
d. |
On August 13, 2025, the Company entered into an
Open Market Sale Agreement (the “Sales Agreement”) with a sales agent. In accordance with the terms of the Sales Agreement,
the Company may offer and sell its ordinary shares from time to time through the sales agent, having an aggregate offering price of up
to $75,000.
The Sales Agreement is subject to certain limitations on the number of shares to be sold in any single day and any minimum price below
sales may not be made. |
As
of December 31, 2025, the Company issued 9,252,639 ordinary
shares of no-par value under the Sales Agreement for a total consideration of $13,272,
net of sales agent fees and other issuance costs of $1,023.
|